Download the fact sheet
Humanized tumor microenvironment, three-dimensional drug screening and patient-derived xenograft verification platform
BioDuro’s hTME-3DX Screen and Verify™ is a 2-step preclinical tumor testing platform to identify the most efficacious oncology drug candidates and potential patient populations:
- SCREEN with confidence: Ex vivo humanized 3D culture with 300 primary patient tumors
- VERIFY for assurance: In vivo matched patient-derived xenograft models
Advanced Models for Human Cancer
BioDuro’s 300 hTME-3DX Screen and Verify™ models
- Primary human tumor samples from the world’s largest bank of clinically annotated viable cryopreserved tumor cells
- Molecular characterization of all tumor models
- Established from US population, with matched histology/path review and associated ex vivo treatment data
- Matching DNA, RNA and protein available for screening targets of interest
- Profiled against a panel of 25+ SOC drugs, with clinically validated diagnostic testing for Extreme Drug Resistance (EDR) recorded as extreme, intermediate, or low
Additional benefits of hTME-3DX Screen and Verify™ models
- Reduce animal testing in preclinical phases
- Maintain throughput capability while using complex tumor models
- Achieve greater cost and time efficiencies in drug screening
- Rationalized workflow from 3D drug screening to PDX verification with the same set of patient tumors
- Enable further characterization, in vivo, PK, PD experiments, and broader MoA studies to increase relevance of overall data package